This is the opinion of a classical blood group serologist work ing in this field for 40 years. Using the tools of serology, nearly all problems in the daily transfusion routine could be solved. The upcoming PCR tests for RBC typing were a welcome help for clarification of dubious reactions some of them being mentioned in this place. In rare situations lack of difficultly available or even not existent test reagents prevented testing of particular antigens and hindered the confirmation of sus pected specificities of antibodies against RBC antigens. Some of the commercially available test antibodies produced only partial agglutination patterns of the RBCs under investiga tion, sometimes leading to doubts in the interpretation of the results. This unwanted phenomenon was observed especially when tests for M, N, Lutheran, and Duffy b antigens were performed. With the appearance of the monoclonal antibo dies some of these problems could be solved. Furthermore, over the years the number of ABO discrepancies revealing a misfit between forward and reverse grouping piled up and awaits an explanation. With the availability of DNA typing for RBC antigens in the 1990s an explanation of the pheno menon could be offered: presence of the respective ABO gene on the nucleotide level and lack of antigen expression on the RBC membrane turned out to be the cause for the discrepancies in many individuals, or the presence of vari ant ABO genes resulted in serologically nondetectable ABO antigens [1] . Also the acquired B phenomenon, a potential cause for ABOincompatible transfusions [2] could easily be resolved using DNA analysis, demonstrating the lack of the B gene. The Bombay phenotype which could be diagnosed by serological means using an antiH lectin gained final proof by genotyping. Blood samples giving mixedfield reactions in tube and slide tests or twocell population patterns in micro column tests could be traced back to their real genetic back ground: Reactions of this type were found in polytransfused patients, in recipients of bone marrow or stem cell transplants and in leukemic patients loosing partially their ABO antigens. In some individuals showing twocell populations in tests for Rh antigens, DNA sequencing revealed deletions at the RH gene locus developing on the basis of hematological disorders [3]. In the rare chimeras where the minor cell population can reflect the true genotype DNA analysis is a perfect tool for safe diagnosis. Genotyping of different blood group antigens poses a great step forward in patients with positive DAT, in polytransfused patients, and in blood samples showing polyag glutination where serological procedures often fail to give cor rect results. As far as problems in ABO typing are concerned, clinical transfusion problems regarding the selection of com patible blood are managed by circumventing the present iso antibodies. But as long as guidelines require reverse grouping (what I strongly recommend), DNA typing for ABO group ing needs serologic antibody test for confirmation. With the exception of rare patients presenting antibodies against high frequency antigens, or patients with antibody mixtures, com patible crossmatchnegative RBCs could be provided for the vast majority of the recipients. Serologic methods can be hand led easily, they are quick and simple, and they cause mostly tolerable costs. Costs explode when donors have to be tested serologically on a large scale for certain antigens to find suit able blood units for patients with problematic antibodies.
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Particularly for smaller transfusion laboratories, which can not afford DNA technology, the antigenantibody reaction based serological methods will be useful tools also in future, especially in urgent pretransfusion testing for unit selection and compatibility testing.
Highthroughput genotyping will become quicker and cheaper offering the chance to test the donor population for the whole antigen profile of the most important blood group systems and to facilitate the provision of suitable blood units for patients with multiple antibodies. Further largescale donor genotyping for the absence of highfrequency antigens and the collection and cryopreservation of the respective units will provide a broader basis for the collaboration of national and international blood centers in covering the demands of recipients with antibodies against these highfrequency anti gens. The migration and mixture of populations will change the antigen composition of future donors and recipients and the profile of the appearing antibodies. The annual statistics of the antibodies found in recipients and pregnant women help determine what blood group markers should be tested primarily. The extension to all major blood group systems will be rational.
Genotyping of the whole RBC antigen profile of potential blood recipients makes sense only for individuals requiring chronic transfusion support, to minimize alloimmunization by selection of antigennegative RBCs. For patients sporadically being transfused the risk of immunization seems to be bearable even in view of the ongoing efforts to screen the donor popula tion for the antigens of the most important RBC systems.
Screening of phenotypically RhDpositive and weak D positive pregnant women on the DNA level would indicate the women prone to produce alloantiD after exposure by an RhDpositive fetus. As a consequence the serologically RhD positive individuals belonging to category D VII should receive antiD prophylaxis, whereas the prophylaxis can be omitted in all weak D types except the types 4,2, 15, and 38. This is an economically interesting issue because independent of the number of pregnancies the test has to be done only once in lifetime.
The idea of matching the antigen profiles of recipients and donors to prevent exposure to foreign antigens has practical limitations. Regarding the clinically most important blood group systems ABO, Rh, Kell, Kidd and Duffy, the chance to have the individually required appropriate number of units on the shelf is minimal. The ulterior motive for this strategy was to skip the serological crossmatch and to replace it by electronic matching. Taking into account all the possible in compatibilities with blood group markers not tested for, even when DNA technology will be implemented on a broader basis (private antigens), this approach remains a form of the Russian roulette. The author would refuse to receive a RBC unit without a serologic crossmatch! One should never forget that the biological playground for blood group incompatibilities is the protein and sugar level, and not the nucleotide level. The question may be raised whether genotyping is the only reliable method to test for an tigens or whether there could occur pitfalls in the technology. Whatever technique is used, we have to be aware of possible methodologydependent faults in the procedure. In serology antibodies are used for antigen typing. These antibodies may not always be of optimal quality, or an appropriate antibody may not bind to the antigen because of antigenic variants. In genotyping the primer may not bind to the target nucleotide sequence due to mutations that do not necessarily alter the functionality of the resulting antigen. Amplification does not occur, leading to the conclusion that the respective gene is missing! In contrast the primer binds to the sequence searched for indicating the presence of the gene, but the respective an tigen is not expressed due to a mutation in the promoter of the gene, rendering the gene inactive. These are two exam ples that under certain circumstances serology and genotyp ing do not always give identical typing results. When testing a specific individual, these complexities should be kept in mind. The problem has no major influence on largescale screening of blood donors because to the opinion of the author the an tigens tested by genotyping should be confirmed by serology before the selected blood unit is released for the prospective recipient. A positive side effect of full antigen genotyping is the possibility to find suitably matched donors for the produc tion of cell panels for antibody identification.
Surveillance and clinical guidance of pregnancies threat ened by maternal antibodies will in near future surely be done by fetal genotyping from maternal plasma. So far typing of the nominated father was an unsafe method for prediction of an tigen positivity of the fetus -be it heterozygosity or the 'pater semper incertus' consideration. The latter situation is a typical example for the future coexistence of genotyping and serol ogy as antibodies can only be documented by serology.
Blood grouping in the context of transfusion medicine means testing for antigens and antibodies! Blood groupspe cific antigen determinants are proteins or sugars, and their re action partners, the immunoglobulins, are proteins containing sugars -so, why not testing for antibodies on the nucleotide level? It has been estimated that an IgG molecule can be pro duced in at least more than 2.6 × 10 6 different ways [4] , which of course does not imply that we would have to perform the same number of tests. In transfusion medicine we look for antibody specificities, and the specificity is predominantly de fined by the sequence of amino acids forming the tips of the six polypeptide loops of the antigen binding site of the anti body molecule. The specific arrangement of the amino acids is the result of the exposure to an antigen. The RhD antigen for example is composed of at least 30 different epitopes. Conse quently antiD antibodies, despite showing the same specifi city, differ from each other. Therefore sequencespecific typ ing with primers or sequencing of all antibody specificities di rected to blood group markers would be a neverending task.
Genotyping of blood group antigens in the above men tioned situations is an enormous progress and will have a great impact on optimization of patient care in transfusion medicine and motherchild blood group incompatibilities.
